期刊文献+

植入式压力反射刺激装置治疗顽固性高血压的研究进展 被引量:1

Advances of Implanted Baroreflex Stimulation for Treatment of Resistant Hypertension
下载PDF
导出
摘要 高血压患者使用了3种或3种以上的降压药物包括利尿剂在内而难以使血压得到有效的控制,称为顽固性高血压。血压的调节涉及多种因素,主要为内皮功能、自主神经、肾素-血管紧张素系统三种调节系统。药物虽能作用于各调节系统,但对于顽固性高血压患者疗效却有限,近年来有两种新技术用于抗交感神经治疗顽固性高血压,即肾动脉交感神经射频消融术和植入式压力反射刺激装置,现就后者作一综述。 Resistant hypertension is defined as blood pressure that is beyond control in spite of using three antihypertensive agents of different classes including diuretics. Blood pressure regulation involves multiple factors, 3 main important factors of which are autonomic nervous system, endothelial system and renin-angiotensin-aldosterone system. Though drugs may block regulation systems, its effects in resist- ant arterial hypertension are limited. Recently, two new techniques, radiofrequency ablation of renal artery sympathetic and implanted baroreflex stimulation, are applied to the treatment of resistant arterial hypertension through antisympathetic. We will review the latter device in this article.
出处 《心血管病学进展》 CAS 2013年第6期766-770,共5页 Advances in Cardiovascular Diseases
关键词 植入式压力反射刺激装置 顽固性高血压 颈动脉窦 压力感受器 implanted baroreflex stimulation resistant hypertension carotid sinus baroreceptor
  • 相关文献

参考文献23

  • 1Mohaupt MG,Schmidli J,Luft FC,et al.Management of uncontrollable hypertension with a carotid sinus stimulation device[J].Hypertension,2007,50(5):825-828.
  • 2Lloyd-Jones D,Adams RJ,Brown TM,et al.Heart disease and stroke statistics-2010 update:a report from the American Heart Association[J].Circulation,2010,121(7):46-215.
  • 3Papademetriou V,Doumas M,Faselis C,et al,Carotid baroreceptor stimulation for the treatment of resistant hypertension[J].Int J Hypertens,2011,2011:964394.
  • 4Cooper A.In Reflexogenic Areas of the Cardiovascular System[R].Edited by Heymans C.London:J&A Churchill,Heymans C,Neil E,1858:457.
  • 5Hering H.Der Karotisdruckversuch[J].Münch Med Wochenschr,1923,1278-1290.
  • 6陈莉,程文立.难治性高血压的病因和治疗研究进展[J].中国全科医学,2012,15(26):2974-2977. 被引量:39
  • 7Bilgutay AM,Lillehei CW.Treatment of hypertension with an implantable electronic device[J].JAMA,1965,191:649-653.
  • 8Neistadt A,Schwartz SI.Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension[J].Surgery,1967,61(6):923-931.
  • 9Carlsten A,Folkow B,Grimby G,et al.Cardiovascular effects of direct stimulation of the carotid sinus nerve in man[J].Acta Physiol Scand,1958,44(2):138-145.
  • 10Brest AN,Wiener L,Bachrach B.Bilateral carotid sinus nerve stimulation in the treatment of hypertension[J].Am J Cardiol,1972,29(6):821-825.

二级参考文献29

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2619
  • 2Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [ J ]. JAMA, 2003, 289 (19): 2560-2572.
  • 3Mancia G, De Backer G, Dominiezak A, et al. 2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the Man- agement of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hy- pertens, 2007, 25 (6): 1105-1187.
  • 4Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment. A scientific statement from the Amer- ican Heart Association Professional Education Committee of the Council for High Blood Pressure Research [ J ]. Hypertension, 2008, 51 (6): 1403 -1419.
  • 5Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high - risk hypertensive patients randomly assigned to calcium channel bloc- ker versus angiotensin - converting enzyme inhibitor in the antihypertens- ive and lipid -lowering treatment to prevent heart attack trial [ J]. Hy- pertension, 2006, 48 (3): 374-384.
  • 6Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive pa- tients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J]. Lancet, 2004, 363 (9426) : 2022 -2031.
  • 7Hannila - Handelberg T, Kontula K, Tikkanen I, et al. Common vari- ants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hyperten- sion [J]. BMC Med Genet, 2005, 6: 4.
  • 8Givens RC, Lin YS, Dowling AL, et al. CYP3A.5 genotype predicts renal CYP3A activity and blood pressure in healthy adults [ J]. J Appl Physiol, 2003, 95 (3) : 1297 -1300.
  • 9Picketing TG, Hall JE, Appel LJ, et 81. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the A- merican Heart Association Council on High Blood Pressure Research [J]. Circulation. 2005. 111 (5): 697-716.
  • 10Hall JE. The kidney, hypertension, and obesity [J]. Hypertension, 2003, 41 ( 2): 625-633.

共引文献39

同被引文献31

  • 1A1-Ansary LA,Tqcco AC, Adi Y,et al. A Systematic Review of Recent Clinical Practice Guidelines on the Diagnosis,assessment and Management of Hypertension[J].PLOS ONE,2013,8:e53744.
  • 2Zhang Y,Zhang X,Liu L,et al. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy[J]. J Hypertens,2012,30( 11 ):2202-12.
  • 3Liu L,Zhang Y,Liu G,et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients[J]. J Hypertens,2005,23(12):2157-72.
  • 4James PA,Oparil S,Carter BL,et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth ~oint National Committee(JNC8) [J].JAMA,2014,311(5):507-20.
  • 5Mancia G,Fagard R,Narkiewicz K. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC) [J].European Heart Journal,2013,34(28):2159-219.
  • 6Sever PS,Messerli FH. Hypertension management 2011: optimal combination therapy[J]. Eur Heart J,2011,32(20):2499-506.
  • 7Gradman AH,Basile JN,Carter BL,Bakris GL. Combination therapy in hypertension[J]. J Am Soc Hypertens,2010,4(1):42-50.
  • 8Salahuddin A,Mushtaq M,Materson BJ. Combination therapy for hypertension 2013: An update[J]. J Am Soc Hypertens,2013,7(5):401-7.
  • 9舒永华,肖文星,周群.复方降压制剂新进展[J].医药前沿,2013(6):15-6.
  • 10薛原.单片复方制剂成高血压治疗趋势[N].健康报,2013,006:1-2.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部